COMMUNIQUÉS West-GlobeNewswire

Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors
08/10/2025
AlphaMedix TM ( 212 Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors AlphaMedix TM showed [...]
Portzamparc – Groupe BNP Paribas initie la couverture d’ONWARD Medical avec une recommandation d’Achat et un objectif de cours de 10,20 EUR
08/10/2025
EINDHOVEN, Pays-Bas, 08 oct. 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext : ONWD), société leader dans le domaine des neurotechnologies visant au développement de thérapies innovantes destinées à la [...]
Portzamparc – BNP Paribas Group Initiates Coverage of ONWARD Medical with a Buy Rating and Target Price of EUR 10.20
08/10/2025
EINDHOVEN, the Netherlands, Oct. 08, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and [...]
Philips announces 5,000th Zenition mobile C-arm system installation, advancing access to high-quality, efficient surgical and interventional care worldwide
08/10/2025
October 8, 2025 Global adoption milestone underscores innovation in mobile C-arm surgical and interventional imaging, with more than 15 million patients treated in 170+ countries every year Amsterdam, the Netherlands – [...]
Macomics Announces Neurodegeneration and Neuroinflammation Applications of ENIGMAC Drug Discovery Platform
08/10/2025
EDINBURGH and CAMBRIDGE, United Kingdom, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery, announces that it has validated its ENIGMAC™ platform in neurodegeneration and [...]
Communiqué de presse : AlphaMedixTM (212Pb-DOTAMTATE) a satisfait l’ensemble des critères d’évaluation principaux d’efficacité lors de l’essai de phase 2, démontrant des bénéfices cliniquement significatifs chez les patients atteints (...)
08/10/2025
AlphaMedix TM ( 212 Pb-DOTAMTATE) a satisfait l’ensemble des critères d’évaluation principaux d’efficacité lors de l’essai de phase 2, démontrant des bénéfices cliniquement significatifs chez les patients atteints de [...]
Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors
08/10/2025
AlphaMedix TM ( 212 Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors AlphaMedix TM showed [...]
Communiqué de presse : AlphaMedixTM (212Pb-DOTAMTATE) a satisfait l’ensemble des critères d’évaluation principaux d’efficacité lors de l’essai de phase 2, démontrant des bénéfices cliniquement significatifs chez les patients atteints (...)
08/10/2025
AlphaMedix TM ( 212 Pb-DOTAMTATE) a satisfait l’ensemble des critères d’évaluation principaux d’efficacité lors de l’essai de phase 2, démontrant des bénéfices cliniquement significatifs chez les patients atteints de [...]
NJ-Founded MetasTx Fast-Tracks Precision Approach to Stop Prostate Cancer Spread; NCI-Backed Diagnostic in Proof-of-Concept, Next-Gen KIT Inhibitor Advancing Toward First-in-Human
07/10/2025
PITTSBURGH, Oct. 07, 2025 (GLOBE NEWSWIRE) -- MetasTx, an early-stage biotech originally founded in New Jersey and now headquartered in Pittsburgh, announced progress on its two-part precision oncology platform designed [...]
Inventiva présentera plusieurs abstracts lors du congrès AASLD The Liver Meeting® 2025
07/10/2025
Présentation d’une comparaison entre histologie numérique et sur lame des biopsies de screening de l’étude de Phase 3 NATiV3 Présentation de pathologie numérique de données précliniques avec lanifibranor Daix (France), [...]
Inventiva to Present Multiple Abstracts at AASLD The Liver Meeting® 2025
07/10/2025
Presentation of a comparison between digital and glass slide histology from screening biopsies in the Phase 3 NATiV3 study Presentation of digital pathology data from preclinical studies with lanifibranor Daix (France [...]
AAVantgarde announces 3 presentations at ESGCT 2025 annual meeting
07/10/2025
MILAN, Oct. 07, 2025 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, today announced three presentations at the [...]
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07/10/2025
VANCOUVER, British Columbia and BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, [...]
ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 of 2025
07/10/2025
PORTLAND, Maine, Oct. 07, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and [...]
Neurona Expands Investigation of NRTX-1001 Cell Therapy into Mesial Temporal Lobe Epilepsy (MTLE) without Mesial Temporal Sclerosis (MTS)
07/10/2025
- First subject received unilateral administration of NRTX-1001 in a new non-MTS cohort; no significant surgical complications or adverse events reported to date - - Data from this non-MTS cohort, together with results [...]
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
07/10/2025
CONSHOHOCKEN, Pa., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated [...]
Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
07/10/2025
WEST CHESTER, Pa., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical [...]
Reviva to Participate in Key Opinion Leader Webinar Hosted by Alliance Global Partners
07/10/2025
CUPERTINO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet [...]
Triumph Steps Expands Emotional Literacy Programs to Schools Nationwide
07/10/2025
New Curriculum Empowers Students, Educators, and Families to Build Resilience and Purpose Together Miami, Florida , Oct. 07, 2025 (GLOBE NEWSWIRE) -- Triumph Steps , an emotional literacy platform trusted by [...]

Pages